Welcome to the InfoSci Platform
Reference Hub1
Knowledge and Quality Innovation in the Health Sector: The Role of Public Research Organisations

Knowledge and Quality Innovation in the Health Sector: The Role of Public Research Organisations

Arturo Torres-Vargas, Javier Jasso-Villazul
Copyright: © 2014 |Pages: 30
ISBN13: 9781466647695|ISBN10: 1466647698|EISBN13: 9781466647701
DOI: 10.4018/978-1-4666-4769-5.ch008
Cite Chapter Cite Chapter

MLA

Torres-Vargas, Arturo, and Javier Jasso-Villazul. "Knowledge and Quality Innovation in the Health Sector: The Role of Public Research Organisations." Quality Innovation: Knowledge, Theory, and Practices, edited by Latif Al-Hakim and Chen Jin, IGI Global, 2014, pp. 159-188. https://doi.org/10.4018/978-1-4666-4769-5.ch008

APA

Torres-Vargas, A. & Jasso-Villazul, J. (2014). Knowledge and Quality Innovation in the Health Sector: The Role of Public Research Organisations. In L. Al-Hakim & C. Jin (Eds.), Quality Innovation: Knowledge, Theory, and Practices (pp. 159-188). IGI Global. https://doi.org/10.4018/978-1-4666-4769-5.ch008

Chicago

Torres-Vargas, Arturo, and Javier Jasso-Villazul. "Knowledge and Quality Innovation in the Health Sector: The Role of Public Research Organisations." In Quality Innovation: Knowledge, Theory, and Practices, edited by Latif Al-Hakim and Chen Jin, 159-188. Hershey, PA: IGI Global, 2014. https://doi.org/10.4018/978-1-4666-4769-5.ch008

Export Reference

Mendeley
Favorite

Abstract

In the pursuit of innovation and quality, firms interact with other organizations, such as firms, universities, research centres, and governmental institutions, to exchange, gain, and develop various kinds of knowledge and other resources. This chapter explores the role of Public Research Organizations (PRO)1 in the innovation process of the health sector in Mexico. Patient indicators are used in order to give account of the role of PRO in that process. Some patterns are identified regarding PROs’ main research and inventive activities and the type of collaboration they have had with other agents. Findings substantiate that collaboration between PRO and other actors are too weak. However, they have built capabilities orientated to the development of artefacts (new or improved products), methods (for diagnosis, clinical testing, and attack of particular diseases) and vaccines-substances (for tackling existing or new diseases).

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.